Fidelity Investments
MLTX icon

Fidelity Investments’s MoonLake Immunotherapeutics MLTX Stock Holding History

Fidelity Investments’s Portfolio MLTX Stock Details MLTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.68M Sell
143,559
-12,717
-8% -$211K ﹤0.01% 2544
2025
Q4 		$2.06M Sell
156,276
-570,656
-79% -$6.73M ﹤0.01% 2608
2025
Q3 		$5.21M Sell
726,932
-5,003,617
-87% -$261M ﹤0.01% 2226
2025
Q2 		$270M Sell
5,730,549
-596,465
-9% -$24.3M 0.02% 705
2025
Q1 		$247M Sell
6,327,014
-14,377
-0.2% -$619K 0.02% 719
2024
Q4 		$343M Buy
6,341,391
+1,391,167
+28% +$71M 0.02% 603
2024
Q3 		$250M Buy
4,950,224
+1,306,215
+36% +$61.2M 0.02% 749
2024
Q2 		$160M Sell
3,644,009
-726,643
-17% -$30.8M 0.01% 865
2024
Q1 		$220M Buy
4,370,652
+522,974
+14% +$28.4M 0.01% 753
2023
Q4 		$232M Buy
3,847,678
+450,425
+13% +$23.2M 0.02% 690
2023
Q3 		$194M Buy
3,397,253
+19,508
+0.6% +$1.08M 0.02% 713
2023
Q2 		$172M Buy
3,377,745
+2,902,313
+610% +$78.1M 0.01% 775
2023
Q1 		$10.2M Buy
475,432
+289,932
+156% +$4.87M ﹤0.01% 1869
2022
Q4 		$1.95M Sell
185,500
-633,677
-77% -$5.64M ﹤0.01% 2378
2022
Q3 		$6.52M Sell
819,177
-374,113
-31% -$2.64M ﹤0.01% 2077
2022
Q2 		$6.26M Buy
1,193,290
+290
+0% +$1.82K ﹤0.01% 2162
2022
Q1 		$13.2M Hold
1,193,000
– – ﹤0.01% 2003
2021
Q4 		$11.8M Buy
+1,193,000
New +$11.9M ﹤0.01% 2049

Other funds holding MLTX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $5.91B AUM 42.42% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Fidelity Investments's MLTX Position: Q1 2026 in Review

Fidelity Investments reduced its MoonLake Immunotherapeutics (MLTX) stake by 8.1% in Q1 2026, selling an estimated $211K and leaving 143,559 shares worth $2.68M. The position accounts for ﹤0.01% of the portfolio, ranked #2544.

Fidelity Investments first reported a position in MLTX in Q4 2021 and has held it in 18 quarters since. The position peaked at $343M in Q4 2024. 147 funds tracked by Wall St. Rank hold MLTX as of Q1 2026.

  • Fidelity Investments held 143,559 shares of MoonLake Immunotherapeutics worth $2.68M as of Q1 2026.
  • Fidelity Investments sold 12,717 MoonLake Immunotherapeutics shares in Q1 2026, an estimated $211K.
  • MoonLake Immunotherapeutics made up ﹤0.01% of Fidelity Investments's portfolio in Q1 2026, its #2544 holding.
  • Fidelity Investments first reported a position in MoonLake Immunotherapeutics in Q4 2021 and has held it in 18 quarters since.
  • Fidelity Investments's MoonLake Immunotherapeutics position peaked at $343M in Q4 2024.
  • 147 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q1 2026.

Based on Fidelity Investments's 13F filing for Q1 2026, filed 15 May 2026.